Target‐organ protection with combination renin‐angiotensin‐system blockade

Pharmacologic blockade of the renin‐angiotensin‐aldosterone system (RAS) has antihypertensive, anti‐atherogenic, antioxidant, and anti‐inflammatory effects. Treatment with angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) has been demonstrated to prevent atrial fibrillation and new‐onset diabetes, and provide cardiac, cerebral, and renal protection. Combination therapy with ACEIs and ARBs, compared with monotherapy, provides enhanced reno‐ and cardioprotection, although available data indicate that combination RAS blockade may be beneficial only in select patient groups, such as those with diabetes mellitus, chronic kidney disease, or heart failure (HF). In certain high‐risk patients, the use of ARBs provides comparable efficacy to that observed with ACEIs. The efficacy of these agents may stem from pleiotropic effects beyond blood pressure (BP) reduction. Several studies demonstrate achievement of clinical endpoints without significant effects on BP. Copyright © 2009 Wiley Periodicals, Inc.     

EDTA‐induced pseudo‐neutropenia resolved with kanamycin

This report describes a case of spurious neutropenia caused by EDTA‐dependent in vitro agglutination of neutrophils. After raising the temperature of the sample to 37°C the agglutination was irreversible, but it resolved completely after addition of kanamycin. Previously this method has been shown to be effective in EDTA‐dependent pseudo‐thrombocytopenia, but this is the first report demonstrating successful application in EDTA‐dependent pseudo‐neutropenia.     

Use of positron emission tomography with methyl‐11C‐choline and 2‐18F‐fluoro‐2‐deoxy‐D‐glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium

Objective

To compare positron emission tomography (PET) and magnetic resonance imaging (MRI) in the evaluation of inflammatory proliferation of synovium.

Methods

Ten patients (mean ± SD age 36 ± 13 years) with inflammatory joint disease and with clinical signs of inflammation of the joint were studied. A new tracer for cellular proliferation, methyl‐¹¹C‐choline (¹¹C‐choline), and a widely used tracer for the detection of inflammation and cancer, 2‐¹⁸F‐fluoro‐2‐deoxy‐D ‐glucose (¹⁸F‐FDG), were applied for PET imaging, and the results were compared with the findings from gadolinium diethylenetriaminepentaacetic acid–enhanced MR images. The uptake of ¹¹C‐choline and ¹⁸F‐FDG in the inflamed synovium was measured and expressed as the standardized uptake value (SUV) and the kinetic influx constant (K_i) obtained from graphic analysis, and these values were compared with quantitative values on MRI. Synovial volumes were measured on the coronal contrast‐enhanced T1‐weighted MR images using the standard software of the MR imager.

Results

All patients showed high accumulation of both ¹¹C‐choline and ¹⁸F‐FDG at the site of arthritic changes, where quantification of the tracer uptake was performed. The SUV of ¹¹C‐choline was 1.5 ± 0.9 gm/ml (mean ± SD; n = 10) and the SUV of ¹⁸F‐FDG was 1.9 ± 0.9 gm/ml (n = 10) (P = 0.017). The K_i of ¹¹C‐choline (mean ± SD 0.048 ± 0.042 minute⁻¹) was 8‐fold higher than the K_i of ¹⁸F‐FDG (0.006 ± 0.003 minute⁻¹) (P = 0.009). Both the uptake of ¹¹C‐choline and the uptake of ¹⁸F‐FDG correlated highly with the volume of synovium; the highest correlation was observed with the K_i of ¹¹C‐choline (r = 0.954, P < 0.0001).

Conclusion

In the use of PET scans,¹¹C‐choline can be regarded as a promising tracer for quantitative imaging of proliferative arthritis changes. Nevertheless, subsequent prospective studies with larger numbers of patients are necessary to further characterize the relationship between the findings on PET imaging and the clinical and functional measures of inflammation.

     

T‐cell‐rich B‐cell lymphoma of the spleen presenting with severe hypersplenism

We report a 19‐year‐old woman who was presented with B‐symptoms, massive splenomegaly, hepatomegaly and hypersplenism. She underwent diagnostic/therapeutic splenectomy. Microscopically, the spleen showed a vaguely micronodular and diffuse proliferation of lymphoid cells in the white pulp that also involved the red pulp. On immunohistochemical staining, this proliferation consisted predominantly of CD3⁺, CD7⁺ small T cells with the presence of a minor populat?on of CD15^?,CD30^?, CD20⁺ large atypical B cells. A liver biopsy also showed a similar morphology to that seen in the spleen. After splenectomy, only the pancytopenia improved. A combined immunochemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) was utilized, which resulted in a complete remission.     

Point‐of‐care ultrasound with pocket‐size devices in emergency department

Point‐of‐care ultrasound is a useful tool for clinicians in the management of patients. Particularly in emergency department, the role of point‐of‐care ultrasound is strongly increasing due to the need for a rapid assessment of critically ill patients and to speed up the diagnostic process. Hand‐carried ultrasound devices are particularly useful in emergency setting and allow rapid assessment of patient even in prehospital setting. This article will review the role of point‐of‐care ultrasonography, performed with pocket‐size devices, in the management of patients presenting with acute onset of undifferentiating dyspnea, chest pain, and shock in emergency department.     

Patient‐Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon‐ and Ribavirin‐Free Regimens

The purpose of the study was to assess the effect of different treatment regimens for chronic hepatitis C on patient‐reported outcomes (PROs) of individuals aged 65 and older with chronic hepatitis C. PRO data from eight multinational multicenter Phase 2 and 3 clinical trials were included. Of 3,120 participants in these clinical trials, 229 were aged 65 and older (67.8 ± 3.2, 57% male, 75% treatment‐naïve, 22% cirrhotic), and 90 of those received ledipasvir plus sofosbuvir (LDV + SOF), 119 received SOF plus ribavirin (SOF + RBV), and 20 received pegylated IFN, SOF, and RBV (IFN + SOF + RBV). Participants aged 65 and older had slightly more pretreatment PRO impairment in their physical functioning than younger individuals (?3.1% on a normalized 0–100% PRO scale, P < .001). Despite this, these participants experienced significant PRO improvement during treatment with IFN‐free RBV‐free regimens (up to +8.0%, P < .001), similar to improvements in younger participants. In contrast, participants aged 65 and older experienced substantial decline in PROs while receiving IFN‐ or RBV‐containing regimens (up to ?18.9% in IFN + SOF + RBV, ?10.4% in IFN‐free SOF+RBV, P < .001), and some were greater than in the younger group. Nevertheless, after achieving sustained viral clearance at Posttreatment Week 12, PROs in participants aged 65 and older improved regardless of the regimen (up to +10.4%, P < .001). In multivariate analysis of the cohort aged 65 and older, the use of IFN and RBV was consistently associated with PRO impairment during treatment. The use of an IFN‐ and RBV‐free anti‐HCV regimen in older adults with hepatitis C results in significant improvement of PROs.